Enanta Pharmaceuticals (ENTA) Current Deferred Revenue (2012 - 2014)

Enanta Pharmaceuticals (ENTA) has 3 years of Current Deferred Revenue data on file, last reported at $51000.0 in Q1 2014.

• Quarterly Current Deferred Revenue fell 55.65% year-over-year to $51000.0 in Q1 2014, while the trailing twelve-month figure through Mar 2014 was $51000.0 (down 55.65% YoY) and the FY2013 annual result came in at $10000.0, down 41.18% from the prior year.
• Current Deferred Revenue grew to $51000.0 in Q1 2014, from $5000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $115000.0 in Q1 2013 to a low of $5000.0 in Q4 2013.
• A 3-year average of $39600.0 and a median of $17000.0 in 2012 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2013 — Current Deferred Revenue plunged 41.18% — and 2014, when it sank 55.65%.
• Tracing ENTA's Current Deferred Revenue over 3 years: stood at $17000.0 in 2012, then plunged by 70.59% to $5000.0 in 2013, then surged by 920.0% to $51000.0 in 2014.
• The last three Current Deferred Revenue figures came in at $51000.0 (Q1 2014), $5000.0 (Q4 2013), and $10000.0 (Q3 2013), per Business Quant data.